

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/013604 A2

(51) International Patent Classification⁷: **A61K 45/00**

(21) International Application Number: PCT/IB02/03544

(22) International Filing Date: 6 August 2002 (06.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/311,388 9 August 2001 (09.08.2001) US

(71) Applicant (*for all designated States except US*): **GENSET S.A.** [FR/FR]; Intellectual Property Department, 24, Rue Royale, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LUCAS, John** [US/US]; 339 The Valley Road, Concord, MA 01742 (US). **DIALYNAS, Deno** [US/US]; 3425 Lebon Drive, #813, San Diego, CA 92122 (US). **BRIGGS, Kristen** [US/US]; 2454 Mango Way, Del Mar, CA 92014 (US).

(74) Common Representative: **GENSET S.A.**; c/o De Luca, Giampiero, Serono International S.A., Intellectual Property, 12, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF METABOLIC DISORDERS WITH MIGENIX AGONISTS AND ANTAGONISTS

(57) Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of MIGENIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.



WO 03/013604 A2

TREATMENT OF METABOLIC DISORDERS WITH MIGENIX

AGONISTS AND ANTAGONISTS

Field of the Invention

5 The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and maintaining weight loss and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. The present invention additionally
10 relates elsewhere to the field of metabolic research, in particular the discovery of compounds effective for increasing body mass and useful for treating disorders associated with excessive weight loss. Applicant reserves the right to exclude any of the aforesaid obesity-related diseases or disorders. The disorders associated with excessive weight loss and envisioned to be treated by the methods of the invention include, but are not limited to, cachexia, cancer-related weight loss, AIDS-
15 related weight loss, chronic inflammatory disease-related weight loss, and anorexia. Applicant reserves the right to exclude any of the aforesaid disorders associated with excessive weight loss.

In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of MIGENIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

20

Background of the Invention

The following discussion is intended to facilitate the understanding of the invention, but is not intended nor admitted to be prior art to the invention.

Obesity is a public health problem that is serious, widespread, and increasing. In the United States, 20 percent of the population is obese; in Europe, a slightly lower percentage is obese
25 (Friedman (2000) Nature 404:632-634). Obesity is associated with increased risk of hypertension, cardiovascular disease, diabetes, and cancer as well as respiratory complications and osteoarthritis (Kopelman (2000) Nature 404:635-643). Even modest weight loss ameliorates these associated conditions.

Recently it was shown that particular carboxyl-terminal fragments of the full-length
30 ACRP30 (mouse) and APM1 (human) polypeptides have unexpected effects *in vitro* and *in vivo*, including utility for weight reduction, prevention of weight gain, and control of blood glucose levels (Fruebis et al (2001) Proc Natl Acad Sci USA 98:2005-10). The effects of ACRP30 fragment administration in mammals also include reduction of elevated free fatty acid levels including elevated free fatty acid levels caused by administration of epinephrine, *i.v.* injection of "intralipid",

or administration of a high fat test meal, as well as increased fatty acid oxidation in muscle cells, and weight reduction in mammals consuming a normal or high fat/high sucrose diet.

Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification
5 referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.

Summary of the Invention

APM1 belongs to an expanding family of related secreted polypeptides that includes among others C2P, ZADJ-2 and ZADJ-7. These polypeptides have in common the structure: signal
10 peptide, N-terminally disposed unique region, collagen-like region, and globular C-terminal C1q homology domain. APM1, C2P, ZADJ-2 and ZADJ-7 further share an NGLXXD amino acid motif C-terminally disposed within the globular domain within a loop implicated in receptor binding, wherein said receptor is MIGENIX. Fragments of APM1, C2P, ZADJ-2 and ZADJ-7 polypeptide comprising the globular domain are herein referred to as gAPM1, gC2P, gZADJ-2 and gZADJ-7. It
15 is further taken to be understood herein that LIGAND refers to a composition consisting essentially of or consisting of *in vitro* or *in vivo* self-assembling homotrimer comprised of gAPM1, gC2P, gZADJ-2, or gZADJ-7 polypeptide fragment.

MIGENIX is a member of the Tumor Necrosis Factor Receptor Super Family (TNFRSF) and is a Type I transmembrane protein. The instant invention is based on MIGENIX as receptor for
20 LIGAND that mediates effects, including utility for weight reduction, maintenance of weight loss, prevention of weight gain, increased insulin sensitivity, and control of blood glucose levels in humans and other mammals. These effects in mammals of MIGENIX engagement by LIGAND also include reduction of elevated free fatty acid levels including elevated free fatty acid levels including elevated free fatty acid levels caused by administration of epinephrine, *i.v.* injection of "intralipid",
25 or administration of a high fat test meal, as well as increased fatty acid oxidation in muscle cells, and weight reduction in mammals consuming a normal or high fat/high sucrose diet. More specifically, the present invention is directed to MIGENIX to which LIGAND binds and through which LIGAND mediates said effects.

In particular, the invention provides for methods of identifying and using AGONISTS and
30 ANTAGONISTS of MIGENIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity, as well as to pharmaceutical and physiologically acceptable compositions comprising said MIGENIX AGONISTS or ANTAGONISTS and methods of administering said pharmaceutical and physiologically acceptable compositions in order to increase or reduce body weight, maintain weight loss, or to treat obesity-
35 related diseases and disorders. Assays for identifying AGONISTS and ANTAGONISTS of obesity-related activity are also part of the invention.

Preferably said MIGENIX AGONIST or ANTAGONIST is a compound selected from the group consisting of polypeptide, polypeptide fragment, peptide, proein, antibody, carbohydrate, lipid, small molecular weight organic compound and small molecular weight inorganic compound.

Preferably said MIGENIX AGONIST or ANTAGONIST is a compound that selectively
5 binds to the extracellular domain of MIGENIX.

In other embodiment, said MIGENIX AGONIST or ANTAGONIST is a compound that selectively binds to the intracellular domain of a polypeptide comprising the extracellular domain of MIGENIX.

The present invention also provides a method of assaying test compounds to identify a test
10 compound that binds to MIGENIX polypeptide. The method comprises contacting MIGENIX polypeptide with a test compound and to determine the extent of binding of the test compound to said MIGENIX polypeptide. The method further comprises determining whether such test compounds are AGONISTS or ANTAGONISTS of MIGENIX polypeptide. The present invention further provides a method of testing the impact of molecules on the expression of MIGENIX
15 polypeptide or on the activity of MIGENIX polypeptide.

The present invention also relates to diagnostic methods of identifying individuals or non-human animals having elevated or reduced levels of MIGENIX products, which individuals are likely to benefit from therapies to suppress or enhance MIGENIX expression, respectively, and to methods of identifying individuals or non-human animals at increased risk for developing, or present
20 state of having, certain diseases/disorders associated with MIGENIX abnormal expression or biological activity.

The present invention provides for methods of identifying AGONISTS of MIGENIX polypeptide biological activity comprising contacting a small molecule compound with MIGENIX polypeptides and measuring MIGENIX polypeptide biological activity in the presence and absence
25 of these small molecules. The present invention further provides for methods of identifying ANTAGONISTS of MIGENIX polypeptide biological activity comprising contacting a small molecule compound with MIGENIX polypeptides and measuring MIGENIX polypeptide biological activity in the presence and absence of these small molecules. These small molecules can be a naturally occurring medicinal compound or derived from combinatorial chemical libraries.

30 The present invention also relates to pharmaceutical or physiologically acceptable compositions comprising, an active agent, including AGONIST or ANTAGONIST of the present invention.

In a first aspect, the invention is directed to MIGENIX AGONISTS, wherein said AGONIST is an antibody that specifically binds MIGENIX, a compound excluding said MIGENIX

antibody (e.g., small organic or inorganic compound, protein, peptide, carbohydrate, lipid), or a LIGAND polypeptide or fragment thereof.

In a further preferred embodiment, the invention is directed to a MIGENIX AGONIST, wherein said AGONIST is an antibody that specifically binds MIGENIX. More preferably the invention is directed to said MIGENIX antibody, wherein said MIGENIX antibody binds MIGENIX and manifests LIGAND activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein.

In a further preferred embodiment, the invention is directed to a MIGENIX AGONIST, wherein said AGONIST is a compound excluding said MIGENIX antibody. More preferably the invention is directed to said compound, wherein said compound binds MIGENIX and manifests LIGAND activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. Further more preferably the invention is directed to said compound, wherein said compound manifests LIGAND activity exclusive of binding to MIGENIX, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. Further more preferably the invention is directed to said compound, wherein said compound increases MIGENIX expression.

In a further preferred embodiment, the invention is directed to a MIGENIX AGONIST that selectively binds to a polypeptide comprising the extracellular domain of MIGENIX.

In a further preferred embodiment, the invention is directed to a MIGENIX AGONIST, wherein said AGONIST is LIGAND, and wherein it is understood that LIGAND refers to a composition consisting essentially of or consisting of *in vitro* or *in vivo* self-assembling homotrimer comprised of gAPM1, gC2P, gZADJ-2, or gZADJ-7 polypeptide fragment. More preferably the invention is directed to said LIGAND, wherein said LIGAND binds MIGENIX and elicits biological activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. More preferably the invention is directed to said LIGAND, wherein said LIGAND induces, enhances, or potentiates said biological activity exclusive of binding to MIGENIX. In preferred embodiment, said homotrimer is comprised of preferred gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment.

APM1. Preferred gAPM1 polypeptide fragment is selected from amino acids **18-244**, **34-244**, 49-244, 56-244, 59-244, 66-244, 69-244, 78-244, 85-244, 93-244, 101-244, 102-244, 103-244, 104-244, 107-244, **110-244** or **113-244**, wherein said numbering of said amino acids within APM1 amino acid sequence is understood to be taken from said APM1 amino acid sequence presented in Table 2. Less preferred gAPM1 fragments are indicated in bold.

C2P. Preferred gC2P polypeptide fragment is selected from amino acids **20-333**, 25-333, 43-333, 45-333, 46-333, 50-333, 53-333, 61-333, 67-333, 74-333, 75-333, 77-333, 81-333, 82-333,

86-333, 89-333, 95-333, 100-333, 104-333, 113-333, 116-333, 125-333, 128-333, 140-333, 160-333, 164-333, 179-333, 182-333, 185-333, 188-333, 191-333, 193-333, or **202-333**, wherein said numbering of said amino acids within C2P amino acid sequence is understood to be taken from said C2P amino acid sequence presented in Table 2. Less preferred gC2P fragments are indicated in
5 bold.

ZADJ-2. Preferred gZADJ-2 polypeptide fragment is selected from amino acids **16-285**, **25-285**, **26-285**, **29-285**, **30-285**, 91-285, 93-285, 97-285, 98-285, 99-285, 105-285, 109-285, 112-285, 120-285, 126-285, 127-285, 130-285, 132-285, 133-285, 134-285, or **150-285**, wherein said numbering of said amino acids within ZADJ-2 amino acid sequence is understood to be taken from
10 said ZADJ-2 amino acid sequence presented in Table 2. Less preferred gZADJ-2 fragments are indicated in bold.

ZADJ-7. Preferred gZADJ-7 polypeptide fragment is selected from amino acids **31-303**, **39-303**, 78-303, 81-303, 84-303, 85-303, 88-303, 91-303, 97-303, 99-303, 109-303, 117-303, 118-303, 127-303, 139-303, 142-303, **155-303**, or **162-303**, wherein said numbering of said amino acids
15 within ZADJ-7 amino acid sequence is understood to be taken from said ZADJ-7 amino acid sequence presented in Table 2. Less preferred gZADJ-7 fragments are indicated in bold.

More preferred LIGAND is APM1.

In a further preferred embodiment, said AGONIST is able to lower circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

20 Further preferred AGONISTS are those that significantly stimulate muscle lipid or free fatty acid oxidation as compared to untreated cells. Further preferred AGONISTS are those that cause C2C12 cells differentiated in the presence of said AGONISTS to undergo at least 10%, 20%, 30%, 35%, or 40% more oleate oxidation as compared to untreated cells.

Further preferred AGONISTS are those that increase by at least 10%, 20%, 30%, 35%, or
25 40% leptin uptake in a liver cell line [preferably BPRCL mouse liver cells (ATCC CRL-2217)] as compared to untreated cells.

Further preferred AGONISTS are those that significantly reduce the postprandial increase in plasma free fatty acids or triglycerides, particularly following a high fat meal.

Further preferred AGONISTS are those that significantly reduce or eliminate ketone body
30 production, particularly following a high fat meal.

Further preferred AGONISTS are those that increase glucose uptake in skeletal muscle cells.

Further preferred AGONISTS are those that increase glucose uptake in adipose cells.

Further preferred AGONISTS are those that increase glucose uptake in neuronal cells.

Further preferred AGONISTS are those that increase glucose uptake in red blood cells.

Further preferred AGONISTS are those that increase glucose uptake in the brain.

Further preferred AGONISTS are those that significantly reduce the postprandial increase in plasma glucose following a meal, particularly a high carbohydrate meal.

Further preferred AGONISTS are those that significantly prevent the postprandial increase
5 in plasma glucose following a meal, particularly a high fat or a high carbohydrate meal.

Further preferred AGONISTS are those that improve insulin sensitivity.

Further preferred said AGONISTS are those that decrease body mass, wherein said decrease in body mass is comprised of a change in mass of the subcutaneous adipose tissue.

Further preferred said AGONISTS are those that decrease body mass, wherein said decrease
10 in body mass is comprised of a change in mass of the visceral (omental) adipose tissue.

In a second aspect, the invention features a pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of, said AGONIST described in the first aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

In a third aspect, the invention features a method of reducing body mass comprising
15 providing or administering to individuals in need of reducing body mass said pharmaceutical or physiologically acceptable composition described in the second aspect.

In a fourth aspect, the invention features a method of preventing or treating an obesity-related disease or disorder comprising providing or administering to an individual in need of such treatment said pharmaceutical or physiologically acceptable composition described in the second
20 aspect. Preferably, said obesity-related disease or disorder is selected from the group consisting of obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions,
25 retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by said MIGENIX AGONIST of the invention include hyperlipidemia and hyperuricemia. In preferred embodiments, said individual is a mammal, preferably a human.

In related aspects, embodiments of the present invention includes methods of causing or
30 inducing a desired biological response in an individual comprising the steps of: providing or administering to an individual a composition comprising AGONIST, wherein said biological response is selected from the group consisting of:

- (a) lowering circulating (either blood, serum, or plasma) levels (concentration) of free fatty acids;

- (b) lowering circulating (either blood, serum or plasma) levels (concentration) of glucose;
- (c) lowering circulating (either blood, serum or plasma) levels (concentration) of triglycerides;
- 5 (d) stimulating muscle lipid or free fatty acid oxidation;
- (c) increasing leptin uptake in the liver or liver cells;
- (e) reducing the postprandial increase in plasma free fatty acids, particularly following a high fat meal;
- (f) reducing or eliminating ketone body production, particularly following a high fat meal;
- 10 (g) increasing tissue sensitivity to insulin, particularly muscle, adipose, liver or brain,

and further wherein said biological response is significantly greater than, or at least 10%, 20%, 30%, 35%, or 40% greater than that observed in the absence of treatment; or alternatively wherein said biological response is greater than a transient response; or alternatively wherein said biological response is sustained. In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control blood glucose in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) in combination with insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control blood glucose in some persons with Insulin Dependent Diabetes Mellitus (IDDM, Type I diabetes) in combination with insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control body weight in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) in combination with insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control body weight in some persons with Insulin Dependent Diabetes Mellitus (IDDM, Type I diabetes) in combination with insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control blood glucose in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) alone, without combination of insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control blood glucose in some persons with Insulin Dependent Diabetes Mellitus (IDDM, Type I diabetes) alone, without combination of insulin therapy.

5 In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control body weight in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) alone, without combination of insulin therapy.

10 In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to control body weight in some persons with Insulin Dependent Diabetes Mellitus (IDDM, Type I diabetes) alone, without combination of insulin therapy.

In a further preferred embodiment, the present invention may be used in complementary therapy of NIDDM patients to improve their weight or glucose control in combination with an insulin secretagogue or an insulin sensitising agent. Preferably, the insulin secretagogue is 1,1-dimethyl-2-(2-morpholino phenyl)guanidine fumarate (BTS67582) or a sulphonylurea selected from tolbutamide, tolazamide, chlorpropamide, glibenclamide, glimepiride, glipizide and glidazide. Preferably, the insulin sensitising agent is selected from metformin, ciglitazone, troglitazone and pioglitazone.

20 The present invention further provides a method of improving the body weight or glucose control of NIDDM patients alone, without an insulin secretagogue or an insulin sensitising agent.

In a further preferred embodiment, the present invention may be used in complementary therapy of IDDM patients to improve their weight or glucose control in combination with an insulin secretagogue or an insulin sensitising agent. Preferably, the insulin secretagogue is 1,1-dimethyl-2-(2-morpholino phenyl) guanidine fumarate (BTS67582) or a sulphonylurea selected from tolbutamide, tolazamide, chlorpropamide, glibenclamide, glimepiride, glipizide and glidazide. Preferably, the insulin sensitising agent is selected from metformin, ciglitazone, troglitazone and pioglitazone.

The present invention further provides a method of improving the body weight or glucose control of IDDM patients alone, without an insulin secretagogue or an insulin sensitising agent.

35 In a further preferred embodiment, the present invention may be administered either concomitantly or concurrently, with the insulin secretagogue or insulin sensitising agent for example in the form of separate dosage units to be used simultaneously, separately or sequentially (either before or after the secretagogue or either before or after the sensitising agent). Accordingly, the present invention further provides for a composition of pharmaceutical or physiologically acceptable

composition and an insulin secretagogue or insulin sensitising agent as a combined preparation for simultaneous, separate or sequential use for the improvement of body weight or glucose control in NIDDM or IDDM patients.

In further preferred embodiments, the present invention of said pharmaceutical or
5 physiologically acceptable composition further provides a method for the use as an insulin sensitiser.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to improve insulin sensitivity in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) in combination with insulin therapy.

10 In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method to improve insulin sensitivity in some persons with Insulin Dependent Diabetes Mellitus (IDDM, Type I diabetes) in combination with insulin therapy.

In further preferred embodiments, the present invention of said pharmaceutical or
15 physiologically acceptable composition can be used as a method to improve insulin sensitivity in some persons with Noninsulin Dependent Diabetes Mellitus (NIDDM, Type II diabetes) without insulin therapy.

In a fifth aspect, the invention features a use of AGONIST described in the first aspect for treatment of obesity-related diseases and disorders and/or reducing body mass. Preferably, said
20 obesity-related diseases and disorders are selected from the group consisting of obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions, retinopathy, neuropathy,
25 and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by said AGONIST of the invention include hyperlipidemia and hyperuricemia.

In a sixth aspect, the invention features a use of AGONIST described in the first aspect for the preparation of a medicament for the treatment of obesity-related diseases and disorders and/or
30 for reducing body mass. Preferably, said obesity-related disease or disorder is selected from the group consisting of obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular
35 lesions, retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related

disorders to be treated by compounds of the invention include hyperlipidemia and hyperuricemia. In preferred embodiments, said individual is a mammal, preferably a human.

In a seventh aspect, the invention provides AGONIST of the first aspect of the invention, or a composition of the second aspect of the invention, for use in a method of treatment of the human
5 or animal body.

In an eighth aspect, the invention features methods of reducing body weight comprising providing to an individual said pharmaceutical or physiologically acceptable composition described in the second aspect, or AGONIST described in the first aspect. Where the reduction of body weight is practiced for cosmetic purposes, the individual has a BMI of at least 20 and no more than 25. In
10 embodiments for the treatment of obesity, the individual may have a BMI of at least 20. One embodiment for the treatment of obesity provides for the treatment of individuals with BMI values of at least 25. Another embodiment for the treatment of obesity provides for the treatment of individuals with BMI values of at least 30. Yet another embodiment provides for the treatment of individuals with BMI values of at least 40.

15 In further embodiment, the invention features methods of maintaining weight loss comprising providing to an individual said pharmaceutical or physiologically acceptable composition.

In a ninth aspect, the invention features the pharmaceutical or physiologically acceptable composition described in the second aspect for reducing body mass and/or for treatment or
20 prevention of obesity-related diseases or disorders. Preferably, said obesity-related disease or disorder is selected from the group consisting of obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention
25 include microangiopathic lesions, ocular lesions, retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by compounds of the invention include hyperlipidemia and hyperuricemia. In preferred embodiments, said individual is a mammal, preferably a human. In preferred embodiments, the identification of said individuals to be treated
30 with said pharmaceutical or physiologically acceptable composition comprises genotyping LIGAND single nucleotide polymorphisms (SNPs) or measuring LIGAND polypeptide or mRNA levels in clinical samples from said individuals. Preferably, said clinical samples are selected from the group consisting of blood, serum, plasma, urine, and saliva.

In a tenth aspect, the invention features the pharmaceutical or physiologically acceptable
35 composition described in the second aspect for reducing body weight for cosmetic reasons.

In an eleventh aspect, AGONIST of the invention is used in methods of treating insulin resistance comprising providing to an individual said pharmaceutical or physiologically acceptable composition described in the second aspect, or AGONIST described in the first aspect.

In a preferred aspect of the methods above and disclosed herein, the amount of AGONIST
5 administered to an individual is sufficient to bring levels of MIGENIX activation to their normal levels (levels in individuals without obesity-related disease or disorder). "Normal levels" of MIGENIX activation may be followed using surrogate markers including circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

In a twelfth aspect, the invention is directed to a MIGENIX ANTAGONIST, wherein said
10 ANTAGONIST is a soluble fragment of MIGENIX polypeptide, an antibody that specifically binds MIGENIX, a compound excluding said soluble fragment of MIGENIX polypeptide and said MIGENIX antibody (e.g., small molecular weight organic or inorganic compound, protein, peptide, carbohydrate, lipid), or a variant or fragment of LIGAND polypeptide.

In a further preferred embodiment, the invention is directed to a MIGENIX ANTAGONIST,
15 wherein said ANTAGONIST is a soluble fragment of MIGENIX polypeptide. More preferably the invention is directed to purified, isolated, or recombinant soluble fragments of MIGENIX polypeptide. More preferably the invention is directed to said soluble fragment of MIGENIX polypeptide, wherein said soluble fragment binds LIGAND and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-
20 like activity or described herein, and wherein said soluble fragment of MIGENIX polypeptide does not activate MIGENIX. Preferably said soluble fragment of MIGENIX polypeptide blocks or inhibits LIGAND binding to MIGENIX. In preferred embodiments, said soluble fragment of MIGENIX polypeptide comprises, consists essentially of, or consists of, at least 6 and not more than
222 consecutive amino acids of SEQ ID NO:2, more preferably of amino acids comprising the
25 extracellular domain of MIGENIX. Preferred said soluble fragment of MIGENIX comprises the extracellular domain of mature MIGENIX polypeptide. Particularly preferred soluble fragment of MIGENIX comprises amino acids 29-192, 29-194, 29-198, 29-206, 29-215, 29-218, 29-222, 29-229,
29-235, 29-240, 29-242, 29-245, 29-249 or 29-250 of SEQ ID NO:2, where it is understood that amino acid 29 is predicted to be the N-terminal amino acid of the mature MIGENIX polypeptide
30 absent the putative signal peptide. In other preferred embodiments, said soluble fragment of MIGENIX polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the corresponding consecutive amino acids of SEQ ID NO:2. Further preferred embodiments include heterologous polypeptides comprising a
35 MIGENIX polypeptide of the invention. In further preferred embodiment, a MIGENIX polypeptide of the invention is conjugated at its N- or C-terminus to an antibody Fc region or portion thereof.

In a further preferred embodiment, the invention is directed to a MIGENIX ANTAGONIST, wherein said ANTAGONIST is an antibody that specifically binds MIGENIX. More preferably the invention is directed to said MIGENIX antibody, wherein said MIGENIX antibody binds MIGENIX and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said
5 MIGENIX antibody does not activate MIGENIX. Preferably said MIGENIX antibody blocks or inhibits LIGAND binding to MIGENIX.

In a further preferred embodiment, the invention is directed to a MIGENIX ANTAGONIST, wherein said ANTAGONIST is a compound excluding said soluble fragment of MIGENIX
10 polypeptide and said MIGENIX antibody (e.g., small organic molecule, protein, peptide). More preferably the invention is directed to said compound, wherein said compound binds to MIGENIX and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate MIGENIX. Preferably said compound that binds to MIGENIX blocks
15 or inhibits LIGAND binding to MIGENIX. Further more preferably the invention is directed to said compound, wherein said compound blocks or inhibits LIGAND activity exclusive of binding to MIGENIX, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate MIGENIX. Further more preferably the invention is directed to said compound, wherein
20 said compound blocks or inhibits MIGENIX expression and wherein said compound does not have LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate MIGENIX.

In a further preferred embodiment, the invention is directed to a MIGENIX ANTAGONIST,
25 wherein said ANTAGONIST is a variant or fragment of LIGAND polypeptide. More preferably the invention is directed to said variant or fragment of LIGAND polypeptide, wherein said variant or fragment of LIGAND polypeptide binds MIGENIX and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said variant or fragment of LIGAND polypeptide does not
30 activate MIGENIX. Preferably said variant or fragment of LIGAND polypeptide blocks or inhibits LIGAND binding to MIGENIX. More preferably the invention is directed to said variant or fragment of LIGAND polypeptide, wherein said variant or fragment of LIGAND polypeptide inhibits the induction, enhancement, or potentiation of said biological activity exclusive of binding to MIGENIX.

35 In a further preferred embodiment, the invention is directed to a MIGENIX ANTAGONIST that selectively binds to a polypeptide comprising the extracellular domain of MIGENIX.

In a further preferred embodiment, said ANTAGONIST is able to raise circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

Further preferred said ANTAGONISTS are those that significantly inhibit muscle lipid or
5 free fatty acid oxidation stimulated by its LIGAND. Further preferred said ANTAGONISTS are those that cause C2C12 cells differentiated in the presence of LIGAND to undergo at least 10%, 20%, 30%, 35%, or 40% less oleate oxidation as compared to untreated cells.

Further preferred said ANTAGONISTS are those that inhibit by at least 10%, 20%, 30%, 35%, or 40% the increase in leptin uptake stimulated by LIGAND polypeptide in a liver cell line
10 [preferably BPRCL mouse liver cells (ATCC CRL-2217)] as compared to untreated cells.

Further preferred said ANTAGONISTS are those that significantly increase the postprandial increase in plasma free fatty acids, particularly following a high fat meal.

Further preferred said ANTAGONISTS are those that significantly increase ketone body production, particularly following a high fat meal.

15 Further preferred said ANTAGONISTS are those that decrease glucose uptake in skeletal muscle cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in adipose cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in neuronal
20 cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in red blood cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in the brain stimulated by LIGAND.

25 Further preferred said ANTAGONISTS are those that significantly increase the postprandial increase in plasma glucose following a meal, particularly a high carbohydrate meal.

Further preferred said ANTAGONISTS are those that significantly facilitate the postprandial increase in plasma glucose following a meal, particularly a high fat or a high carbohydrate meal.

30 Further preferred said ANTAGONISTS are those that reduce the insulin sensitivity stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that increase body mass, wherein said increase in body mass is comprised of a change in mass of the subcutaneous adipose tissue.

Further preferred said ANTAGONISTS are those that increase body mass, wherein said increase in body mass is comprised of a change in mass of the visceral (omental) adipose tissue.

In a thirteenth aspect, the invention features a pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of, said ANTAGONIST described in
5 the twelfth aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

In a fourteenth aspect, the invention features a method of increasing body mass comprising providing or administering to individuals in need of increasing body mass said pharmaceutical or physiologically acceptable composition described in the thirteenth aspect.

In a fifteenth aspect, the invention features a method of preventing or treating disorders
10 associated with excessive weight loss comprising providing or administering to an individual in need of such treatment said pharmaceutical or physiologically acceptable composition described in the thirteenth aspect. Preferably said disorder is selected from the group consisting of cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. Said disorders associated with excessive weight loss are
15 comprised of those mediated by tumor necrosis factor (TNFalpha) alone, those mediated by TNFalpha plus one or more additional factors, and those mediated only by one or more factors exclusive of TNFalpha. Said factors include, but are not restricted to, macrophage migration inhibitory factor, interleukin 1, and interleukin 6. In preferred embodiments, said individual is a mammal, preferably a human.

20 In related aspects, embodiments of the present invention includes methods of causing or inducing a desired biological response in an individual comprising the steps of: providing or administering to an individual a composition comprising ANTAGONIST, wherein said biological response is selected from the group consisting of:

- 25 (a) raising circulating (either blood, serum, or plasma) levels (concentration) of free fatty acids (FFA) or triglycerides (TG);
- (b) raising circulating (either blood, serum or plasma) levels (concentration) of glucose;
- (c) raising circulating (either blood, serum or plasma) levels (concentration) of triglycerides;
- (d) inhibiting muscle lipid or free fatty acid oxidation;
- 30 (e) inhibiting leptin uptake in the liver or liver cells;
- (e) increasing the postprandial increase in plasma free fatty acids, particularly following a high fat meal; and,
- (f) increasing or eliminating ketone body production, particularly following a high fat meal;

(g) reducing tissue sensitivity to insulin, particularly muscle, adipose, liver or brain, and further wherein said biological response is greater than a transient response; or alternatively wherein said biological response is sustained. In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method
5 of increasing body mass in some persons with cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia.

In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition further provides a method for the use as an insulin desensitiser, wherein the sensitivity of a cell or tissue to insulin is reduced.

10 In a sixteenth aspect, the invention features a method of making the MIGENIX polypeptide described in the twelfth aspect, wherein said method is selected from the group consisting of proteolytic cleavage, recombinant methodology and artificial synthesis. In a preferred embodiment, proteolytic cleavage is carried out using trypsin, plasmin, or collagenase.

In a seventeenth aspect, the invention features a use of ANTAGONIST described in the
15 twelfth aspect for the preparation of a medicament for the treatment of disorders associated with excessive weight loss and/or for increasing body mass. Preferably, said disorder is selected from the group consisting of cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. In preferred embodiments, said individual is a mammal, preferably a human.

20 In an eighteenth aspect, the invention provides ANTAGONIST of the twelfth aspect of the invention, or a composition of the thirteenth aspect of the invention, for use in a method of treatment of the human or animal body.

In a nineteenth aspect, the invention features methods of increasing body weight comprising providing to an individual said pharmaceutical or physiologically acceptable composition described
25 in the thirteenth aspect, or ANTAGONIST described in the twelfth aspect. Where the increase of body weight is practiced for cosmetic purposes, the individual has a BMI of no greater than 25 and at least 20. In embodiments for the treatment of disorders associated with excessive weight loss, the individual may have a BMI no greater than 20. One embodiment for the treatment of disorders associated with excessive weight loss provides for the treatment of individuals with BMI values of
30 no greater than 15. Alternatively, for increasing the body weight of an individual, the BMI value should be at least 15 and no more than 20.

In a twentieth aspect, the invention features the pharmaceutical or physiologically acceptable composition described in the thirteenth aspect for increasing body mass and/or for treatment of disorders associated with excessive weight loss. Preferably, said disorder is selected
35 from the group consisting of cachexia, wasting, cancer-related weight loss, AIDS-related weight

loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. In preferred embodiments, said individual is a mammal, preferably a human.

In a twenty-first aspect, the invention features the pharmaceutical or physiologically acceptable composition described in the thirteenth aspect for increasing body weight for cosmetic
5 reasons.

In a preferred aspect of the methods above and disclosed herein, the amount of ANTAGONIST administered to an individual is sufficient to bring levels of MIGENIX activation to their normal levels (levels in healthy individuals). "Normal levels" of MIGENIX activation may be followed using surrogate markers including circulating (either blood, serum or plasma) levels
10 (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

Brief Description of Tables

Table 1 lists known or predicted biologic structural and functional domains for the MIGENIX polypeptide of SEQ ID NO:2 of the present invention, including the signal peptide, extracellular (EC) domain, transmembrane domain, and intracellular (IC) domain.

15 Table 2 lists the amino acid sequence of full-length APM1, C2P, ZADJ-2 and ZADJ-7 polypeptide. The total number of amino acids is given in parentheses. The predicted signal peptide is indicated in bold. The collagen-like region is indicated by dotted line. The region between the predicted signal peptide and the collagen-like region is the N-terminally disposed unique region. The globular C-terminal C1q homology domain is indicated by single underline. The NGLXXD
20 amino acid motif C-terminally disposed within the globular domain is indicated by double underline. It is taken to be understood that C2P herein encompasses variants comprising the substitution of valine for methionine at position 219 and/or the substitution of methionine for valine at position 301.

Structure of MIGENIX Polypeptide

The full-length MIGENIX polypeptide is comprised of at least 4 distinct regions including:

- 25 1. an N-terminal putative signal peptide comprising amino acids from about amino acids 1-28 of SEQ ID NO:2;
2. an extracellular domain comprising a LIGAND binding portion and comprising amino acids from about amino acids 29-250 of SEQ ID NO:2;
3. a transmembrane domain comprising amino acids from about amino acids 251-272
30 of SEQ ID NO:2; and
4. an intracellular domain comprising amino acids from about amino acids 273-427 of SEQ ID NO:2.

Brief Description of Sequence Listing

SEQ ID NO:1 is the nucleotide sequence of cDNA with an open reading frame which location is indicated as features. When appropriate, the locations of the potential polyadenylation site and polyadenylation signal are also indicated.

SEQ ID NO:2 is the amino acid sequence of polypeptide encoded by the cDNA of SEQ ID
5 NO:1.

The appended Sequence Listing is hereby incorporated by reference in its entirety.

Detailed Description

Definitions

Before describing the invention in greater detail, the following definitions are set forth to
10 illustrate and define the meaning and scope of the terms used to describe the invention herein.

The term "isolated" requires that the material be removed from its original environment (e. g., the natural environment if the material is naturally occurring).

The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude,
15 preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

As used interchangeably herein, the term "polynucleotide(s)" include RNA or DNA (either single or double stranded, coding, complementary or antisense), or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form (although each of the above species
20 may be particularly specified).

The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides that are capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region.

The terms "polypeptide" and "protein", used interchangeably herein, refer to a polymer of
25 amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude chemical or post-expression modifications of the polypeptides of the invention, although chemical or post-expression modifications of these polypeptides may be included excluded as specific embodiments.

30 As used herein, the terms "recombinant polynucleotide" and "polynucleotide construct" are used interchangeably to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment. In particular, these terms mean

that the polynucleotide or cDNA is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment.

The term "recombinant polypeptide" is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as
5 contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship.

As used herein, the term "non-human animal" refers to any non-human animal, including
10 insects, birds, rodents and more usually mammals. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

The term "domain" refers to an amino acid fragment with specific biological properties. This term encompasses all known structural and linear biological motifs.

As used herein, the term "receptor" refers to a polypeptide to which a "ligand" binds and
15 through which said "ligand" elicits a biological response comprised of biological activities. Said receptor is preferably MIGENIX of the present invention. Said "ligand" is preferably LIGAND of the present invention. By "receptor activation" is intended "ligand"-mediated alteration of said receptor polypeptide, wherein said alteration is selected from but not limited to the group consisting of receptor alterations associated with said biological response.

20 As used herein, the term "AGONIST" refers to naturally occurring and synthetic compounds capable of inducing, enhancing, or potentiating a biological response comprised of biological activities.

As used herein, the term "ANTAGONIST" refers to naturally occurring and synthetic compounds capable of inhibiting a biological response, inhibiting the induction of a biological
25 response, or inhibiting the potentiation of a biological response, wherein said biological response is comprised of biological activities.

Without being limited by theory, the compounds/polypeptides of the invention are capable of modulating the partitioning of dietary lipids between the liver and peripheral tissues, and are thus believed to treat "diseases involving the partitioning of dietary lipids between the liver and
30 peripheral tissues." The term "peripheral tissues" is meant to include muscle and adipose tissue. In preferred embodiments, the compounds/polypeptides of the invention partition the dietary lipids toward or away from the muscle. In alternative preferred embodiments, the dietary lipids are partitioned toward or away from the adipose tissue. In other preferred embodiments, the dietary lipids are partitioned toward or away from the liver. In yet other preferred embodiments, the
35 compounds/polypeptides of the invention increase or decrease the oxidation of dietary lipids,

preferably free fatty acids (FFA) by the muscle. Dietary lipids include, but are not limited to triglycerides and free fatty acids.

Preferred diseases believed to involve the partitioning of dietary lipids include obesity-related diseases and disorders such as obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions, retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by compounds of the invention include hyperlipidemia and hyperuricemia. Yet other disorders of the invention include disorders associated with excessive weight loss such as cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia.

The terms "comprising", "consisting of" and "consisting essentially of" may be interchanged for one another throughout the instant application, although each retains its normal definition. The term "having" has the same meaning as "comprising" and may be replaced with either the term "consisting of" or "consisting essentially of".

Polypeptides of the Invention

Preferably, polypeptides of the invention are recombinantly produced using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide is operably linked to a promoter into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems are used in forming recombinant polypeptides. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use.

Consequently, a further embodiment of the present invention is a method of making a polypeptide, said method comprising the steps of

- a) obtaining a cDNA encoding said polypeptide;
- b) inserting said cDNA in an expression vector such that the cDNA is operably linked to a promoter; and
- c) introducing said expression vector into a host cell whereby said host cell produces said polypeptide.

In one aspect of this embodiment, the method further comprises the step of isolating the polypeptide. Another embodiment of the present invention is a polypeptide obtainable by the method described in the preceding paragraph.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). In preferred embodiment, 5 recombinant polypeptides of the invention are expressed in mammalian cells.

The invention is drawn, *inter alia*, to isolated, purified or recombinant polypeptides. MIGENIX polypeptides of the invention are useful for increasing (ANTAGONISTS of MIGENIX) body weight either as a cosmetic treatment or for treatment or prevention of diseases and disorders as discussed or described herein. MIGENIX polypeptides are also useful *inter alia* in screening 10 assays for AGONISTS or ANTAGONISTS of MIGENIX activity and for raising MIGENIX-specific antibodies. When used for cosmetic treatments, or for the treatment or prevention of diseases, disorders, or conditions, one or more MIGENIX polypeptides can be provided to a subject. Thus, various fragments of the full-length protein can be combined into a "cocktail" for use in the various treatment regimens. LIGAND polypeptides of the invention are useful for reducing 15 (AGONISTS of MIGENIX) body weight either as a cosmetic treatment or prevention of diseases and disorders as discussed or described herein.

The MIGENIX polypeptides of the present invention are preferably provided in an isolated form, and may be partially or substantially purified.

Modifying MIGENIX biological activity

20 Modifying endogenous MIGENIX biological activity is expressly contemplated by the present invention. The present invention further relates to compounds able to modulate MIGENIX biological activity and methods to use these compounds. Such compounds may interact with MIGENIX polypeptides directly or indirectly.

Candidate AGONISTS and ANTAGONISTS Obtained by Optical Biosensor Methods

25 Compounds interacting with a polypeptide comprising MIGENIX extracellular domain can be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo *et al.* (1995), the disclosures of which are incorporated by reference. This technique permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique, which is based on the surface plasmon resonance (SPR) phenomenon, is 30 presented in more detail in Example 1.

Compounds Modulating MIGENIX Biological Activity

Another method of screening for compounds that modulate MIGENIX biological activity is by measuring the effects of test compounds on specific biological activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or 35 as described herein, in a host cell. In one embodiment, the present invention relates to a method of

identifying an agent that alters MIGENIX activity, wherein a nucleic acid construct comprising the polynucleotide of SEQ ID NO:1 or a fragment thereof encoding full-length MIGENIX polypeptide is introduced into a mammalian host cell. The transfected mammalian host cells are maintained under conditions appropriate for expression of the encoded MIGENIX, whereby the nucleic acid is
5 expressed. The host cells are then contacted with a compound to be assessed (an agent) and an activity of the cells is detected in the presence of the compound to be assessed, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein. Detection of a change in said activity for said transfected host cell, but not in untransfected host cell, in the presence of the agent indicates that the agent alters MIGENIX activity.
10 In a particular embodiment, the invention relates to a method of identifying an agent which is an activator (AGONIST) of MIGENIX activity, wherein detection of an increase of said activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, in the presence of the agent indicates that the agent activates MIGENIX activity. In another particular embodiment, the invention relates to a method of
15 identifying an agent which is an inhibitor (ANTAGONIST) of MIGENIX activity, wherein detection of a decrease of said activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, in the presence of the agent indicates that the agent inhibits MIGENIX activity.

Detection of a change in said MIGENIX activity, said activity being selected from the group
20 consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, can be performed using a variety of techniques as described for representative activities in Examples provided herein.

In a particular embodiment a high throughput screen can be used to identify agents that activate (enhance) or inhibit MIGENIX activity (See e.g., PCT publication WO 98/45438, which
25 disclosure is hereby incorporated by reference in its entirety).

Methods of Screening for Compounds Modulating MIGENIX Activity

The present invention also relates to methods of screening compounds for their ability to modulate (e.g. increase or inhibit) the activity or expression of MIGENIX. More specifically, the present invention relates to methods of testing compounds for their ability either to increase or to
30 decrease activity of MIGENIX. The assays are performed *in vitro* or *in vivo*.

The present invention relates to a method for the screening of a candidate substance for interaction with a polypeptide comprising MIGENIX extracellular domain, said method comprising the following steps:

- a) providing said polypeptide comprising MIGENIX extracellular domain;
- 35 b) obtaining a candidate substance;

- c) bringing into contact said polypeptide with said candidate substance;
- d) detecting the complexes formed between said polypeptide and said candidate substance.

The invention further relates to a method for the production of a pharmaceutical composition comprising a method for the screening of a candidate substance that interact with a MIGENIX polypeptide, fragments or variants thereof and furthermore mixing the identified substance with a pharmaceutically acceptable carrier.

The present invention relates to a method for the screening of a candidate substance for the capacity to increase expression of MIGENIX, said method comprising the following steps:

- 10 a) isolating mRNA from cells which have or have not been contacted with said candidate substance;
- b) carrying out a Northern blot analysis with labeled cDNA probe encoding all or part of MIGENIX polypeptide;
- 15 c) wherein increased signal in cells having been contacted with said candidate substance over that of uncontacted cells is taken to indicate that said candidate substance increases expression of MIGENIX and is an AGONIST of MIGENIX activity; and
- d) wherein decreased signal in cells having been contacted with said candidate substance over that of uncontacted cells is taken to indicate that said candidate substance decreases expression of MIGENIX and is an ANTAGONIST of MIGENIX activity.

Methods of isolating mRNA and carrying out Northern blot analysis are well known to those of ordinary skill in the art.

Preparation of Antibody Compositions

25 Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the MIGENIX protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared by methods well known to those of ordinary skill in the art.

30 Preferably the present invention includes monoclonal and polyclonal antibodies that specifically bind MIGENIX polypeptide fragment comprising the extracellular domain of mature MIGENIX polypeptide. Particularly preferred soluble fragment of MIGENIX comprises amino acids 29-192, 29-194, 29-198, 29-206, 29-215, 29-218, 29-222, 29-229, 29-235, 29-240, 29-242, 29-245,

29-249 or 29-250 of SEQ ID NO:2, where it is understood that amino acid 29 is predicted to be the N-terminal amino acid of the mature MIGENIX polypeptide absent the putative signal peptide.

EXAMPLES

The following Examples are provided for illustrative purposes and not as a means of limitation. One of ordinary skill in the art would be able to design equivalent assays and methods based on the disclosure herein all of which form part of the instant invention.

EXAMPLE 1: Use of Biacore Technology to Detect Specific Binding of a Test Compound to Polypeptide Fragment Comprising MIGENIX Extracellular Domain

Biacore utilizes a biosensor technology for monitoring interactions between two or more molecules in real time, without the use of labels. The molecular classes that can be studied are diverse, ranging from proteins, peptides, nucleic acids, carbohydrates, and lipids to low molecular weight substances and pharmaceuticals.

The detection principle is based on the optical phenomena of surface plasmon resonance, which detects changes in refractive index close to a biosensor surface. In a typical experiment one of the interacting molecules is immobilized or captured (here, polypeptide fragment comprising MIGENIX extracellular domain) to a flexible dextran layer close to the sensor surface. The interacting partner (here, test compound) is flowed across that surface. If an interaction occurs between the two molecules, there is a resulting increase in signal due to the increase in mass at the chip surface.

Soluble polypeptide fragment comprising MIGENIX extracellular domain is attached to the sensor surface via amine coupling chemistry. The dextran is activated using N-hydroxysuccinimide and N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride for 7 minutes. Said MIGENIX polypeptide fragment is diluted in 10mM Na Acetate pH 5.0 at a concentration of 10µg/ml and injected over the activated surface for 7 minutes. The surface is then blocked for 7 minutes using ethanolamine to remove any remaining esters. A blank flow cell absent said MIGENIX polypeptide fragment is set up in parallel and used as a control surface. The running buffer is HBS-EP (0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% Surfactant P20) and the instrument temperature is 25°C.

The test compound is filtered through an Ultrafree-0.5 Centrifugal Filter Device and resuspended in HBS-EP running buffer. The test compound is then diluted 1:10 in HBS-EP and injected over the said MIGENIX polypeptide fragment surface and the blank control surface for 1 minute at a flow rate of 50 µl/min. The sensorgrams from the receptor surface and the control surface are aligned and overlaid.

To obtain the specific binding, the control surface was subtracted from the active surface comprised of said MIGENIX polypeptide fragment.

Example 2: Effect of LIGAND on Muscle Cell Fatty Acid Oxidation

C2C12 cells are differentiated in the presence or absence of 2 µg/mL LIGAND for 4 days. On day 4, oleate oxidation rates are determined by measuring conversion of 1-¹⁴C-oleate (0.2 mM) to ¹⁴CO₂ for 90 min. This experiment can be used to screen for active polypeptides and peptides as well as AGONISTS and ANTAGONISTS or activators and inhibitors of LIGAND receptor.

The effect of LIGAND on the rate of oleate oxidation can be compared in differentiated C2C12 cells (murine skeletal muscle cells; ATCC, Manassas, VA CRL-1772) and in a hepatocyte cell line (Hepa1-6; ATCC, Manassas, VA CRL-1830). Cultured cells are maintained according to manufacturer's instructions. The oleate oxidation assay is performed as previously described (Muoio et al (1999) Biochem J 338;783-791). Briefly, nearly confluent myocytes are kept in low serum differentiation media (DMEM, 2.5% Horse serum) for 4 days, at which time formation of myotubes became maximal. Hepatocytes are kept in the same DMEM medium supplemented with 10% FCS for 2 days. One hour prior to the experiment the media is removed and 1 mL of preincubation media (MEM, 2.5% Horse serum, 3 mM glucose, 4 mM Glutamine, 25 mM Hepes, 1% FFA free BSA, 0.25 mM Oleate, 5 µg/mL gentamycin) is added. At the start of the oxidation experiment ¹⁴C-Oleic acid (1µCi/mL, American Radiolabelled Chemical Inc., St. Louis, MO) is added and cells are incubated for 90 min at 37°C in the absence/presence of 2.5 µg/mL LIGAND. After the incubation period 0.75 mL of the media is removed and assayed for ¹⁴C-oxidation products as described below for the muscle FFA oxidation experiment.

20 EXAMPLE 3: Effect of LIGAND on *In Vitro* Glucose Uptake by Muscle Cells

L6 Muscle cells are obtained from the European Culture Collection (Porton Down) and are used at passages 7-11. Cells are maintained in standard tissue culture medium DMEM, and glucose uptake is assessed using [³H]-2-deoxyglucose (2DG) with or without LIGAND in the presence or absence of insulin (10⁻⁸ M) as has been previously described (Walker, P.S. et al. (1990) Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. JBC 265(3):1516-1523; and Kilp, A. et al. (1992) Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinology 130(5):2535-2544, which disclosures are hereby incorporated by reference in their entireties). Uptake of 2DG is expressed as the percentage change compared with control (no added insulin or LIGAND). Values are presented as mean ± SEM of sets of 4 wells per experiment. Differences between sets of wells are evaluated by Student's t test, probability values p<0.05 are considered to be significant.

EXAMPLE 4: Effect of LIGAND on Mice Fed a High-Fat Diet

Experiments are performed using approximately 6 week old C57Bl/6 mice (8 per group). All mice are housed individually. The mice are maintained on a high fat diet throughout each experiment. The high fat diet (cafeteria diet; D12331 from Research Diets, Inc.) has the following

composition: protein kcal% 16, sucrose kcal% 26, and fat kcal% 58. The fat is primarily composed of coconut oil, hydrogenated.

After the mice are fed a high fat diet for 6 days, micro-osmotic pumps are inserted using isoflurane anesthesia, and are used to provide LIGAND, saline, and an irrelevant peptide to the mice subcutaneously (s.c.) for 18 days. LIGAND is provided at doses of 100, 50, 25, and 2.5 µg/day and the irrelevant peptide is provided at 10 µg/day. Body weight is measured on the first, third and fifth day of the high fat diet, and then daily after the start of treatment. Final blood samples are taken by cardiac puncture and are used to determine triglyceride (TG), total cholesterol (TC), glucose, leptin, and insulin levels. The amount of food consumed per day is also determined for each group.

10 EXAMPLE 5: Effect of LIGAND on Plasma Free Fatty Acid in C57 BL/6 Mice

The effect of LIGAND on postprandial lipemia (PPL) in normal C57BL6/J mice is tested.

The mice used in this experiment are fasted for 2 hours prior to the experiment after which a baseline blood sample is taken. All blood samples are taken from the tail using EDTA coated capillary tubes (50 µL each time point). At time 0 (8:30 AM), a standard high fat meal (6g butter, 6 g sunflower oil, 10 g nonfat dry milk, 10 g sucrose, 12 mL distilled water prepared fresh following Nb#6, JF, pg.1) is given by gavage (vol.=1% of body weight) to all animals.

Immediately following the high fat meal, 25µg a LIGAND is injected i.p. in 100 µL saline. The same dose (25µg/mL in 100µL) is again injected at 45 min and at 1 hr 45 min. Control animals are injected with saline (3x100µL). Untreated and treated animals are handled in an alternating mode.

Blood samples are taken in hourly intervals, and are immediately put on ice. Plasma is prepared by centrifugation following each time point. Plasma is kept at -20°C and free fatty acids (FFA), triglycerides (TG) and glucose are determined within 24 hours using standard test kits (Sigma and Wako). Due to the limited amount of plasma available, glucose is determined in duplicate using pooled samples. For each time point, equal volumes of plasma from all 8 animals per treatment group are pooled.

EXAMPLE 6: Effect of LIGAND on Plasma FFA, TG and Glucose in C57 BL/6 Mice

Briefly, 14 mice re fasted for 2 hours prior to the experiment after which a baseline blood sample is taken. All blood samples are taken from the tail using EDTA coated capillary tubes (50 µL each time point). At time 0 (9:00AM), a standard high fat meal (see Example 6) is given by gavage (vol.=1% of body weight) to all animals. Immediately following the high fat meal, 4 mice are injected 25 µg of LIGAND i.p. in 100µL saline. The same dose (25µg in 100µL) is again injected at 45 min and at 1 hr 45 min. A second treatment group receives 3 times 50 µg LIGAND at the same intervals. Control animals are injected with saline (3x100µL). Untreated and treated animals are handled in an alternating mode.

Blood samples are immediately put on ice. Plasma is prepared by centrifugation following each time point. Plasma is kept at -20 °C and free fatty acids (FFA), triglycerides (TG) and glucose

are determined within 24 hours using standard test kits (Sigma and Wako).

EXAMPLE 7: Effect of LIGAND on FFA following Epinephrine Injection

In mice, plasma free fatty acids increase after intragastric administration of a high fat/sucrose test meal. These free fatty acids are mostly produced by the activity of lipolytic enzymes *i.e.* lipoprotein lipase (LPL) and hepatic lipase (HL). In this species, these enzymes are found in significant amounts both bound to endothelium and freely circulating in plasma. Another source of plasma free fatty acids is hormone sensitive lipase (HSL) that releases free fatty acids from adipose tissue after β -adrenergic stimulation. To test whether LIGAND also regulates the metabolism of free fatty acid released by HSL, mice are injected with epinephrine.

Two groups of mice are given epinephrine (5 μ g) by intraperitoneal injection. A treated group is injected with a LIGAND (25 μ g) one hour before and again together with epinephrine, while control animals receive saline. Plasma is isolated and free fatty acids and glucose are measured.

EXAMPLE 8: Effect of LIGAND on FFA following Intralipid Injection

Two groups of mice are intravenously (tail vein) injected with 30 μ L bolus of Intralipid-20% (Clintec) to generate a sudden rise in plasma FFAs, thus by-passing intestinal absorption. (Intralipid is an intravenous fat emulsion used in nutritional therapy). A treated group (LIGAND-treated) is injected with LIGAND (25 μ g) at 30 and 60 minutes before Intralipid is given, while control animals receive saline. Plasma is isolated and FFAs are measured as described previously. The effect of LIGAND on the decay in plasma FFAs following the peak induced by Intralipid injection is then monitored.

EXAMPLE 9: Effect of LIGAND on Weight Gain and Weight Loss of Mice and on Maintenance of Weight Loss in Mice

In the first experiment, 10-week-old male C57BL/6J mice are put on a very high fat/sucrose purified diet for 19 days to promote weight gain; the average body weight at this time is 30g. The mice are then surgically implanted with an osmotic pump (Alzet, Newark, DE) delivering either 2.5 μ g/day of LIGAND or physiological saline. The mice are continued on the high fat diet and their body weight was recorded over the following 10-day period.

Weight gain by mice treated with saline in contradistinction to weight loss by mice treated with LIGAND is taken as evidence that in this inbred strain of normal mice, a continuous infusion of a daily low dose of LIGAND can prevent weight gain caused by high fat/sucrose feeding, in a sustainable way.

Data are expressed throughout as mean $\pm$ SEM; a p-value < 0.05 is considered statistically significant. Statistical analysis is typically done using either the unpaired Student's t test or the paired Student's t test.

Maintenance of weight loss in mice

In order to demonstrate the ability of LIGAND to maintain weight loss, normal mice are put on a reduced calorie diet to promote weight loss. The reduced calorie diet is continued until the

mice lose 10% of their initial weight. A second group of mice are continued on the reduced calorie diet until the mice lose 20% of their initial weight. The mice are then surgically implanted with an osmotic pump (Alzet, Newark, DE) delivering either 2.5 µg/day of LIGAND or physiological saline. The mice are returned to a normal diet and their body weights are recorded over a 10-day period.

- 5 After 10 days, the outcome wherein mice treated with LIGAND have a lower weight than mice treated with saline is taken to provide evidence that treatment with LIGAND promotes the maintenance of weight loss.

EXAMPLE 10: Assessment of homotrimer formation by gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment.

- 10 Homotrimer formation by gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment is assessed using sedimentation equilibrium in analytical centrifuges, a method that determines molecular weight accurately and independently of other physical factors such as shape.

- Candidate gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment homotrimer is purified, for example using a protocol comprising a method of gel filtration such as 16/60 superdex
 15 200 gel filtration column (Amersham). Said purified candidate gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment homotrimer protein concentration is made 3 µM in 5.7 mM phosphate (pH 7.5), 137 mM NaCl, 2.7 mM KCl. Samples are centrifuged at 8,000 rpm for 18 hours at 10°C in a Beckman XL-A analytical ultracentrifuge before absorbance is recorded. The data are fit globally, using MacNonlin PPC [Johnson ML et al., Biophys J (1981) 36:575-8; Schuster TM et al., Curr
 20 Opin Struct Biol (1996) 6:650-8; Hensley P, Structure (1996) 4:367-73; the disclosures of which are incorporated herein by reference in their entirety] to the following equation that describes the sedimentation of a homogeneous species: $Abs = B + A' \exp[H \times M (x^2 - x_0^2)]$ where Abs = absorbance at radius x, A' = absorbance at reference radius x_0 , $H = (1 - \nu\rho)\omega^2/2RT$, R = gas constant, T = temperature in Kelvin, ν = partial specific volume = 0.71896131 mL/g, ρ = density of solvent =
 25 1.0061 g/mL, ω = angular velocity in radians/s, M = apparent molecular weight, and B = solvent absorbance (blank).

TABLE 1

Amino Acid Residues Comprising the Structural Domains of MIGENIX

5

SEQ ID NO: 2 Description

SIGNAL PEPTIDE	EC DOMAIN	TRANSMEMBRANE DOMAIN	IC DOMAIN
1-28	29-250	251-272	273-427

10 EC, extracellular domain; IC, intracellular domain

APM1, C2P, ZADJ-2 and ZADJ-7

>APM1 polypeptide sequence:

5 **MLLLGAVLLLLALPGHD**QETTTQGGPVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRD
 GTPGEKGEKGDPLIGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYR**SAFSV**GLET
YVTIPNMPIRFTKIFYNQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSFLKKDKAM
LFTYDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYH
DTN (244)

10

> C2P polypeptide sequence:

MRIWWLLLAIEICTGNINSQDTCRQGHPIPGNPGHNGLPGRDGRDGAKGDKGDAGEPG
 RPGSPGKDGTSGEKGGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETG
 PQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGMPGPIGKPGPKGEAGPTGPQGEPGVRGIR
 15 **GWK**GDRGEKGKIGETLVLPK**SAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTC**
HIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDDEVWLQ
VTGGERFNGLFADEDDDTTFTGFLLFSSP (333)

>ZADJ-2 polypeptide sequence:

20 **MIPWVLLACALPCAADPLLGA**FARRDFRKGSPQLVCSLPGPQGPPGPPGAPGPSGMMGRM
 GFPKGDKGDGHDGDRGDSGEEGPPGRTGNRGKPGPKGKAGAIAGRAGPRGPKGVNGTPGK
 HGTPGKKGPKGKKGEPGLPGPCSCSGHTK**SAFSVAVTKSYPRERLPIKFDKILMNEGGHY**
NASSGKFVCGVPGIYYFTYDITLANKHLAIGLVHNGQYRIRTFDANTGNHNDVASGSTILALK
QGDEVWLQIFYSEQNGLFYDPYWTDSLFTGFLIYADQDDPNEV (285)

25

>ZADJ-7 polypeptide sequence:

MGKEDTQETRTEPKMFVLLYVTSFAICASGQPRGNQLKGENYSPRYICSIPGLPGPPGPPG
 ANGSPGPHGRIGLPGRDGRDGRKGEKGEKGTAGLRGKTGPLGLAGEKGDQGETGKKGPIG
 PEGEKGEVGPPIGPPGPKGDRGEQGDPLPGVCRCGSIVLK**SAFSVGITTSYPEERLPIIFNKVL**
 30 **FNEGEHYNPATGKFICAFPGIYYFSYDITLANKHLAIGLVHNGQYRIKTFDANTGNHNDVASG**
STVIYLOPEDEVWLEIFFTDQNGLFSDPGWADSLFSGFLLYVDTDYLDSEDEL (303)

What is claimed is:

1. A method of screening for an AGONIST or an ANTAGONIST of MIGENIX activity.
- 5 2. The method of Claim 1, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, insulin-like activity, free fatty acid oxidation, and weight reduction.
3. An AGONIST or an ANTAGONIST of MIGENIX activity.
4. The AGONIST or the ANTAGONIST of Claim 3, wherein said activity is selected
10 from the group consisting of lipid partitioning, lipid metabolism, insulin-like activity, free fatty acid oxidation, and weight reduction.
5. A pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of the AGONIST or the ANTAGONIST of Claim 3.
6. A method of preventing or treating an obesity-related disease or disorder comprising
15 providing or administering to an individual in need of such treatment the composition of Claim 5.

SEQUENCE LISTING

<110> Genset

<120> TREATMENT OF METABOLIC DISORDERS WITH MIGENIX AGONISTS AND ANTAGONISTS

<130> 141.W01

<150> 60/311,388

<151> 2001-08-09

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3386

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (114) ... (1397)

<400> 1

```

gccgcggcca gctccggcgg gcaggggggg cgctggagcg cagcgcagcg cagcccatc 60
agtccgcaaa gcggaccgag ctggaagtcg agcgctgccg cgggaggcgg gcg atg 116
                                         Met
                                         1

ggg gca ggt gcc acc ggc cgc gcc atg gac ggg ccg cgc ctg ctg ctg 164
Gly Ala Gly Ala Thr Gly Arg Ala Met Asp Gly Pro Arg Leu Leu Leu
                    5                      10                      15

ttg ctg ctt ctg ggg gtg tcc ctt gga ggt gcc aag gag gca tgc ccc 212
Leu Leu Leu Leu Gly Val Ser Leu Gly Gly Ala Lys Glu Ala Cys Pro
                20                      25                      30

aca ggc ctg tac aca cac agc ggt gag tgc tgc aaa gcc tgc aac ctg 260
Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn Leu
                35                      40                      45

ggc gag ggt gtg gcc cag cct tgt gga gcc aac cag acc gtg tgt gag 308
Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val Cys Glu
                50                      55                      60                      65

ccc tgc ctg gac agc gtg acg ttc tcc gac gtg gtg agc gcg acc gag 356
Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val Val Ser Ala Thr Glu
                    70                      75                      80

ccg tgc aag ccg tgc acc gag tgc gtg ggg ctc cag agc atg tcg gcg 404
Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu Gln Ser Met Ser Ala
                    85                      90                      95

ccg tgc gtg gag gcc gac gac gcc gtg tgc cgc tgc gcc tac ggc tac 452
Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly Tyr
                100                      105                      110

tac cag gat gag acg act ggg cgc tgc gag gcg tgc cgc gtg tgc gag 500
Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu Ala Cys Arg Val Cys Glu
                115                      120                      125

```


2

gcg ggc tcg ggc ctc gtg ttc tcc tgc cag gac aag cag aac acc gtg	548
Ala Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn Thr Val	
130 135 140 145	
tgc gag gag tgc ccc gac ggc acg tat tcc gac gag gcc aac cac gtg	596
Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser Asp Glu Ala Asn His Val	
150 155 160	
gac ccg tgc ctg ccc tgc acc gtg tgc gag gac acc gag cgc cag ctc	644
Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gln Leu	
165 170 175	
cgc gag tgc aca cgc tgg gcc gac gcc gag tgc gag gag atc cct ggc	692
Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu Cys Glu Glu Ile Pro Gly	
180 185 190	
cgt tgg att aca cgg tcc aca ccc cca gag ggc tcg gac agc aca gcc	740
Arg Trp Ile Thr Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr Ala	
195 200 205	
ccc agc acc cag gag cct gag gca cct cca gaa caa gac ctc ata gcc	788
Pro Ser Thr Gln Glu Pro Glu Ala Pro Pro Glu Gln Asp Leu Ile Ala	
210 215 220 225	
agc acg gtg gca ggt gtg gtg acc aca gtg atg ggc agc tcc cag ccc	836
Ser Thr Val Ala Gly Val Val Thr Thr Val Met Gly Ser Ser Gln Pro	
230 235 240	
gtg gtg acc cga ggc acc acc gac aac ctc atc cct gtc tat tgc tcc	884
Val Val Thr Arg Gly Thr Thr Asp Asn Leu Ile Pro Val Tyr Cys Ser	
245 250 255	
atc ctg gct gct gtg gtt gtg ggc ctt gtg gcc tac ata gcc ttc aag	932
Ile Leu Ala Ala Val Val Val Gly Leu Val Ala Tyr Ile Ala Phe Lys	
260 265 270	
agg tgg aac agc tgc aag cag aac aag caa gga gcc aac agc cgg cca	980
Arg Trp Asn Ser Cys Lys Gln Asn Lys Gln Gly Ala Asn Ser Arg Pro	
275 280 285	
gtg aac cag acg ccc cca cca gag gga gaa aaa ctc cac agc gac agt	1028
Val Asn Gln Thr Pro Pro Pro Glu Gly Glu Lys Leu His Ser Asp Ser	
290 295 300 305	
ggc atc tcc gtg gac agc cag agc ctg cat gac cag cag ccc cac acg	1076
Gly Ile Ser Val Asp Ser Gln Ser Leu His Asp Gln Gln Pro His Thr	
310 315 320	
cag aca gcc tcg ggc cag gcc ctc aag ggt gac gga ggc ctc tac agc	1124
Gln Thr Ala Ser Gly Gln Ala Leu Lys Gly Asp Gly Gly Leu Tyr Ser	
325 330 335	
agc ctg ccc cca gcc aag cgg gag gag gtg gag aag ctt ctc aac ggc	1172
Ser Leu Pro Pro Ala Lys Arg Glu Glu Val Glu Lys Leu Leu Asn Gly	
340 345 350	
tct gcg ggg gac acc tgg cgg cac ctg gcg ggc gag ctg ggc tac cag	1220
Ser Ala Gly Asp Thr Trp Arg His Leu Ala Gly Glu Leu Gly Tyr Gln	
355 360 365	
ccc gag cac ata gac tcc ttt acc cat gag gcc tgc ccc gtt cgc gcc	1268
Pro Glu His Ile Asp Ser Phe Thr His Glu Ala Cys Pro Val Arg Ala	
370 375 380 385	

ctg	gcc	gcc	ctg	cgc	cgc	atc	cag	cga	gcc	gac	ctc	gtg	gag	agt	ctg	1364
Leu	Ala	Ala	Leu	Arg	Arg	Ile	Gln	Arg	Ala	Asp	Leu	Val	Glu	Ser	Leu	
			405					410					415			

tgc agt gag tcc act gcc aca tcc ccg gtg tga gcccaaccgg ggagcccccg 1417
Cys Ser Glu Ser Thr Ala Thr Ser Pro Val *
420 425

ccccgcccc	cattccgaca	accgatgctc	cagccaaccc	ctgtggagcc	cgcaccccc	1477
ccctttgggg	ggggcccgcc	tggcagaact	gagctcctct	gggcaggacc	tcagagtcca	1537
ggccccaaaa	ccacagccct	gtcagtgcag	cccggtgagg	cccttcactt	ctgaccacac	1597
ttcctgtcca	gagagagaag	tgccctgtct	gcctcccca	ccctgcccct	gccccgtcac	1657
catctcaggc	cacctgcccc	cttctcccac	actgctagggt	gggccagccc	ctcccaccac	1717
agcaggtgtc	atatatgggg	ggccaacacc	agggatggta	ctagggggaa	gtgacaaggc	1777
cccagagact	cagagggagg	aatcgaggaa	ccagagccat	ggactctaca	ctgtgaactt	1837
ggggaacaag	ggtggcatcc	cagtggcctc	aaccctccct	cagcccctct	tgccccccac	1897
cccagcctaa	gatgaagagg	atcggaggct	tgtcagagct	gggagggggt	ttcgaagctc	1957
agcccacccc	cctcattttg	gatatagggt	agtgaggccc	agggagaggc	catgattcgc	2017
ccaaagccag	acagcaacgg	ggaggccaag	tgcaggctgg	caccgccttc	tctaaatgag	2077
gggcctcagg	tttgcttgag	ggcgagggga	gggtggcagg	tgacctttctg	ggaaatggct	2137
tgaagccaag	tcagcttttg	cttccacgct	gtctccagac	ccccacccct	tccccactgc	2197
ctgcccaccc	gtggagatgg	gatgcttgcc	tagggcctgg	tccatgatgg	agtcagggtt	2257
ggggttctgt	gaaaggggtc	tgtctccctc	tgccctgtcc	ctcaggcat	gctctgtgtga	2317
catcagtggc	atggctccag	tgctgtgccc	tccatcccg	catggaccgc	gagctaacac	2377
tggcccttag	aatcagccta	ggggtcaggg	accaaggacc	cctcaccttg	caacacacag	2437
acacacgcac	acacacacac	aggaggagaa	atctcacttt	tctccatgag	ttttttctct	2497
tgggctgaga	ctggatactg	cccggggcag	ctgccagaga	agcatcggag	ggaattgagg	2557
tctgtctggc	cgtcttcact	cgcccccggg	tttggcgggc	caaggactgc	cgaccgaggc	2617
tggagctggc	gtctgtcttc	aagggtttac	acgtggagga	atgctcccc	atcctccct	2677
tccctgcaaa	catggggttg	gctgggcccc	gaagggtgcg	atgaagaaaa	gcggggccagt	2737
gtgggaatgc	ggcaagaagg	aattgacttc	gactgtgacc	tgtggggatt	tctcccagct	2797
ctagacaacc	ctgcaaaagg	ctgttttttc	ctgagcttgg	ccagaagggg	gccatgaggc	2857
ctcagtggac	tttcaccccc	ctccctggcc	tgttctgttt	tgctgaagt	tggagtgagt	2917
gtggctcccc	tctattttag	atgacaagcc	ccaggcaggc	tgtgcgctga	caaccaccgc	2977
tccccagccc	agggttcccc	cagccctgtg	gaagggacta	ggagcactgt	agtaaattggc	3037
aattctttga	cctcaacctg	tgatgagggg	aggaaactca	cctgctggcc	cctcacctgg	3097
gcacctgggg	agtgggacag	agtctgggtg	tattttatttt	cctccccagc	agggtggggag	3157
ggggtttgg	ggcttgcaag	tatgttttag	catgtgtttg	gttctggggc	cccttttttac	3217
tccccttag	ctgagatgga	acccttttct	ccccagctg	ggggccatga	gtccagacc	3277
cccagcaacc	ctcctatcac	ctccctccct	tgccctctgt	gtaatcattt	cttgggcctt	3337
cctgaaactt	acacacaaaa	cgttaagtga	tgaacattaa	atagcaaaq		3386

```
<210> 2
<211> 427
<212> PRT
<213> Homo sapiens
```

<400> 2															
Met	Gly	Ala	Gly	Ala	Thr	Gly	Arg	Ala	Met	Asp	Gly	Pro	Arg	Leu	Leu
1				5					10					15	
Leu	Leu	Leu	Leu	Leu	Gly	Val	Ser	Leu	Gly	Gly	Ala	Lys	Glu	Ala	Cys
			20					25					30		
Pro	Thr	Gly	Leu	Tyr	Thr	His	Ser	Gly	Glu	Cys	Cys	Lys	Ala	Cys	Asn
		35					40					45			
Leu	Gly	Glu	Gly	Val	Ala	Gln	Pro	Cys	Gly	Ala	Asn	Gln	Thr	Val	Cys
	50					55					60				
Glu	Pro	Cys	Leu	Asp	Ser	Val	Thr	Phe	Ser	Asp	Val	Val	Ser	Ala	Thr
65					70					75					80

Glu	Pro	Cys	Lys	Pro	Cys	Thr	Glu	Cys	Val	Gly	Leu	Gln	Ser	Met	Ser
				85					90					95	
Ala	Pro	Cys	Val	Glu	Ala	Asp	Asp	Ala	Val	Cys	Arg	Cys	Ala	Tyr	Gly
			100					105					110		
Tyr	Tyr	Gln	Asp	Glu	Thr	Thr	Gly	Arg	Cys	Glu	Ala	Cys	Arg	Val	Cys
		115					120					125			
Glu	Ala	Gly	Ser	Gly	Leu	Val	Phe	Ser	Cys	Gln	Asp	Lys	Gln	Asn	Thr
		130				135					140				
Val	Cys	Glu	Glu	Cys	Pro	Asp	Gly	Thr	Tyr	Ser	Asp	Glu	Ala	Asn	His
145				150					155					160	
Val	Asp	Pro	Cys	Leu	Pro	Cys	Thr	Val	Cys	Glu	Asp	Thr	Glu	Arg	Gln
			165						170					175	
Leu	Arg	Glu	Cys	Thr	Arg	Trp	Ala	Asp	Ala	Glu	Cys	Glu	Glu	Ile	Pro
			180					185					190		
Gly	Arg	Trp	Ile	Thr	Arg	Ser	Thr	Pro	Pro	Glu	Gly	Ser	Asp	Ser	Thr
		195					200					205			
Ala	Pro	Ser	Thr	Gln	Glu	Pro	Glu	Ala	Pro	Pro	Glu	Gln	Asp	Leu	Ile
		210				215					220				
Ala	Ser	Thr	Val	Ala	Gly	Val	Val	Thr	Thr	Val	Met	Gly	Ser	Ser	Gln
225				230						235					240
Pro	Val	Val	Thr	Arg	Gly	Thr	Thr	Asp	Asn	Leu	Ile	Pro	Val	Tyr	Cys
			245						250					255	
Ser	Ile	Leu	Ala	Ala	Val	Val	Val	Gly	Leu	Val	Ala	Tyr	Ile	Ala	Phe
			260					265					270		
Lys	Arg	Trp	Asn	Ser	Cys	Lys	Gln	Asn	Lys	Gln	Gly	Ala	Asn	Ser	Arg
		275					280					285			
Pro	Val	Asn	Gln	Thr	Pro	Pro	Pro	Glu	Gly	Glu	Lys	Leu	His	Ser	Asp
		290				295					300				
Ser	Gly	Ile	Ser	Val	Asp	Ser	Gln	Ser	Leu	His	Asp	Gln	Gln	Pro	His
305				310						315					320
Thr	Gln	Thr	Ala	Ser	Gly	Gln	Ala	Leu	Lys	Gly	Asp	Gly	Gly	Leu	Tyr
			325						330					335	
Ser	Ser	Leu	Pro	Pro	Ala	Lys	Arg	Glu	Glu	Val	Glu	Lys	Leu	Leu	Asn
			340					345					350		
Gly	Ser	Ala	Gly	Asp	Thr	Trp	Arg	His	Leu	Ala	Gly	Glu	Leu	Gly	Tyr
		355					360					365			
Gln	Pro	Glu	His	Ile	Asp	Ser	Phe	Thr	His	Glu	Ala	Cys	Pro	Val	Arg
		370				375					380				
Ala	Leu	Leu	Ala	Ser	Trp	Ala	Thr	Gln	Asp	Ser	Ala	Thr	Leu	Asp	Ala
385				390						395					400
Leu	Leu	Ala	Ala	Leu	Arg	Arg	Ile	Gln	Arg	Ala	Asp	Leu	Val	Glu	Ser
			405						410					415	
Leu	Cys	Ser	Glu	Ser	Thr	Ala	Thr	Ser	Pro	Val					
			420					425							